Inozyme Pharma
Stock Forecast, Prediction & Price Target

Inozyme Pharma Financial Estimates

Inozyme Pharma Revenue Estimates

Inozyme Pharma EBITDA Estimates

Inozyme Pharma Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$0
 
N/A
$0
 
0%
$0
 
0%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $11.10M
Low: $11.10M
High: $11.10M
avg. 0%
Avg: $96.42M
Low: $96.42M
High: $96.42M
avg. 768.31%
Avg: $200.13M
Low: $200.13M
High: $200.13M
avg. 107.54%
Net Income
 
% change YoY
$-56.41M
 
N/A
$-65.44M
 
-16.01%
$-71.16M
 
-8.74%
Avg: $-122.59M
Low: $-97.97M
High: $-63.24M
avg. -72.25%
Avg: $-143.80M
Low: $-104.19M
High: $-68.42M
avg. -17.30%
Avg: $-52.56M
Low: $-52.56M
High: $-52.56M
avg. 63.44%
Avg: $-13.73M
Low: $-13.73M
High: $-13.73M
avg. 73.86%
EBITDA
 
% change YoY
$-55.97M
 
N/A
$-68.67M
 
-22.69%
$-74.81M
 
-8.93%
Avg: $0
Low: $0
High: $0
avg. 100%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
EPS
 
% change YoY
-$2.39
 
N/A
-$1.73
 
27.61%
-$1.37
 
20.80%
Avg: -$1.57
Low: -$1.89
High: -$1.22
avg. -14.59%
Avg: -$1.71
Low: -$2.01
High: -$1.32
avg. -8.81%
Avg: -$1.01
Low: -$1.01
High: -$1.01
avg. 40.64%
Avg: -$0.27
Low: -$0.27
High: -$0.27
avg. 73.86%
Operating Expenses
 
% change YoY
$56.64M
 
N/A
$68.67M
 
21.23%
$75.64M
 
10.14%
Avg: $0
Low: $0
High: $0
avg. -100%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%
Avg: $0
Low: $0
High: $0
avg. 0%

FAQ

What is Inozyme Pharma stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 11.93% in 2025-2028.

We have gathered data from 6 analysts. Their low estimate is -97.97M, average is -122.59M and high is -63.24M.

What is Inozyme Pharma stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 218.96% in 2025-2028.

We have gathered data from 6 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.

What is Inozyme Pharma stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 22.77% in 2025-2028.

We have gathered data from 6 analysts. Their low earnings per share estimate is -$1.89, average is -$1.57 and high is $-1.22.

What is the best performing analyst?

In the last twelve months analysts have been covering Inozyme Pharma stock. The most successful analyst is Tiago Fauth.